Sponsors

Oncology assays in development

BD Diagnostics and Lab21 are to collaborate to develop oncology assays for the BD MAX fully automated bench-top molecular system. Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD MAX platform for a series of oncology markers, while BD will be responsible for manufacturing and commercialising the tests worldwide.

The first two assays will be designed to detect mutations in the KRAS and BRAF genes. These initial assays were selected because of their current importance in optimising the management of cancer patients. The agreement also includes the development of new nucleic acid extraction procedures from formalin-fixed paraffin-embedded tissue.
www.bd.com
www.lab21.com

Latest Issues

GenQA at ESCV 2025

Thessaloniki Concert Hall
17 September, 2025

IBMS Congress

The International Convention Centre (ICC), Birmingham
22-25 September, 2025

Diagnostics North East Conference 2025

The Catalyst, Newcastle
3 October